Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Paxalisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 136,306Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kazia Launches Paxalisib Immunotherapy Trial In Breast Cancer
    Kazia Launches Paxalisib Immunotherapy Trial In Breast Cancer

    30 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-the-launch-of-a-groundbreaking-trial-with-paxalisib-in-combination-with-immunotherapy-in-women-with-advanced-breast-cancer-302364230.html

    PR NEWSWIRE
    30 Jan 2025
    Share Share
    Kazia Therapeutics Updates Paxalisib Regulatory Pathway
    Kazia Therapeutics Updates Paxalisib Regulatory Pathway

    31 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c-meeting-with-fda-302340490.html

    PR NEWSWIRE
    31 Dec 2024
    Share Share
    Kazia Presents Paxalisib Data For Triple Negative Breast Cancer
    Kazia Presents Paxalisib Data For Triple Negative Breast Cancer

    11 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-data-highlighting-synergistic-activity-between-paxalisib-and-immunotherapy-in-immunotherapy-resistant-triple-negative-breast-cancer-model-at-the-san-antonio-breast-cancer-symposium-302328604.html

    PR NEWSWIRE
    11 Dec 2024
    Share Share
    Kazia prunes failed cancer trial data set to form path to FDA
    Kazia prunes failed cancer trial data set to form path to FDA

    11 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-phase-iiiii-clinical-trial-results-for-paxalisib-in-glioblastoma-302193414.html

    PR NEWSWIRE
    11 Jul 2024
    Share Share
    Kazia Announces The Release Of Pnoc022 Clinical Study Abstract
    Kazia Announces The Release Of Pnoc022 Clinical Study Abstract

    15 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-announces-the-release-of-pnoc022-clinical-study-abstract-highlighting-paxalisib-in-diffuse-midline-glioma-patients-ahead-of-the-society-of-neuro-oncology-2023-annual-meeting-301989147.html

    PR NEWSWIRE
    15 Nov 2023
    Share Share
    Kazia Announces Publication In Cancer Therapeutics Highlighting Paxalisib Data
    Kazia Announces Publication In Cancer Therapeutics Highlighting Paxalisib Data

    10 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-announces-publication-in-molecular-cancer-therapeutics-highlighting-paxalisib-preclinical-data-in-melanoma-301984365.html

    PR NEWSWIRE
    10 Nov 2023
    Share Share